Sumitomo Mitsui Trust Group Inc. Sells 896 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sumitomo Mitsui Trust Group Inc. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 307,289 shares of the biopharmaceutical company’s stock after selling 896 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $172,779,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of REGN. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $628,151,000. Acadian Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on REGN shares. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Citigroup upped their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Finally, Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $791.05.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 8,431 shares of company stock valued at $5,733,521. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 3.6%

Shares of NASDAQ:REGN opened at $768.00 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a market capitalization of $80.72 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 2.16 and a beta of 0.39. The firm has a fifty day moving average of $740.64 and a 200 day moving average of $631.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the company posted $12.46 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.